The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Pharmaceutical Business Review reports that Pfizer (NYSE:PFE) and Novartis (NYSE:NVR) are considering participating in the bidding process to acquire Onyx Pharmaceuticals, (NASDAQ:ONXX) a manufacturer of cancer medicines, following rejection of Amgen’s (NASDAQ:AMGN) $$8.7bn buyout proposal.
Pharmaceutical Business Review reports that Pfizer (NYSE:PFE) and Novartis (NYSE:NVR) are considering participating in the bidding process to acquire Onyx Pharmaceuticals, (NASDAQ:ONXX) a manufacturer of cancer medicines, following rejection of Amgen’s (NASDAQ:AMGN) $$8.7bn buyout proposal.
As quoted in the market news:
Sources familiar to the matter were quoted by Reuters saying that Onyx had again put up itself for sale based upon expressions of interest received from other third parties.
Most recently, South San Francisco-based Onyx with a market value of nearly $9.5bn rejected Amgen’s bid, criticizing that the offer underestimated its operations.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.